No Data
Zhejiang Shapuaisi Pharmaceutical (603168.SH): has obtained the Pharmaceutical registration certificate for sodium bromfenac eye drops.
On January 21, Gelonghui announced that Zhejiang Shapuaisi Pharmaceutical (603168.SH) has received the drug registration certificate for sodium bromfenac eye drops approved and issued by the National Medical Products Administration. The approved sodium bromfenac eye drops are intended for symptomatic treatment of inflammatory diseases in the external eye and anterior segment: blepharitis, conjunctivitis, scleritis (including superficial scleritis), and postoperative inflammation.
Sharp Ace 2024 Annual Results Pre-loss Announcement
Zhejiang Shapuaisi Pharmaceutical (603168.SH): A projected loss of 99.2 million yuan to 0.149 billion yuan for the fiscal year 2024.
Gelonghui reported on January 17 that Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced a performance pre-loss announcement for the year 2024. The financial department's preliminary calculations estimate that the company expects to achieve a net income attributable to the parent company's owners of between -148.8 million yuan to -99.2 million yuan for the year 2024. The company also expects to achieve a net income attributable to the parent company's owners, excluding non-recurring gains and losses, between -129.6 million yuan to -86.4 million yuan for the year 2024.
Individual Investors Are Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.'s (SHSE:603168) Biggest Owners and Were Hit After Market Cap Dropped CN¥372m
Zhejiang Shapuaisi Pharmaceutical Secures Clinical Trial Approval for Eye Drops
Zhejiang Shapuaisi Pharmaceutical (603168.SH): The hydrochloride cetirizine eye drops have received a clinical trial approval notice.
Gelonghui on December 9th, zhejiang shapuaisi (603168.SH) announced that the company's levocetirizine hydrochloride eye drops obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (Notice No.: 2024LP02825), and the company plans to conduct clinical trials after the conditions are met. This product is used to treat eye itching associated with allergic conjunctivitis.
What Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.'s (SHSE:603168) 27% Share Price Gain Is Not Telling You
